Regeneron Pharmaceuticals Investors Prepare for Class Action Against Securities Fraud
Recently, significant news emerged regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), prompting investors to take action against potential securities fraud. Glancy Prongay & Murray LLP has announced that investors suffering financial losses now have an opportunity to spearhead a class action lawsuit. The allegations are serious, asserting that from November 2, 2023, to October 30, 2024, Regeneron’s executives failed to accurately disclose critical financial practices that could mislead investors.
Investors are particularly concerned about several undisclosed practices related to the sales of Eylea, a medication developed by Regeneron. According to the lawsuit, it is alleged that the company engaged in arrangements where it paid credit card fees to its distributors. Impressively, these arrangements stipulated that distributors should not impose additional charges on customers who opted to use credit cards for purchasing Eylea. This practice raises concerns about price inflation, as it effectively allowed Regeneron to subsidize costs, offering a deceptive appearance of reduced prices to end consumers.
The lawsuit claims that the company’s exemptions provided a competitive edge in a market sensitive to pricing — especially among retina practices that often prioritize cost efficiency when using credit cards to purchase anti-VEGF medications. By not openly reporting these credit card fee payments as price concessions, the lawsuit suggests that Regeneron artificially inflated its sales figures for Eylea.
This misleading behavior not only skewed Regeneron's perceived profitability but also violated federal regulations by overstating the Average Selling Price (ASP) reported to governmental bodies. Such actions allegedly contravene the False Claims Act, further complicating the company's legal standing.
Now, affected investors are being encouraged to participate before the deadline of March 10, 2025, which marks the conclusion for lead plaintiff applications. To be included in the lawsuit, investors don't need to take proactive measures immediately. They have the option to engage legal counsel of their choosing or remain an absent member of the class action.
For those interested in asserting their rights or seeking further information, Glancy Prongay & Murray LLP has offered resources for contacting their offices. Investors are advised to reach out, ensuring to provide necessary details such as mailing address, phone number, and shares purchased in connection to Regeneron Pharmaceuticals.
In the broader perspective, this unfolding scenario highlights crucial elements of corporate responsibility and investor protection within the healthcare sector. The potential outcomes of this lawsuit could have far-reaching implications, not only for Regeneron but also for the standards of disclosures and ethical practices across the pharmaceutical industry as a whole. Investors remain hopeful that justice and transparency prevail, allowing them to reclaim their financial losses and contribute to a more accountable corporate landscape.
As the case develops, updates will likely continue to emerge, shedding further light on the ongoing struggles between pharmaceutical corporations and their investors. Stakeholders and observers are highly advised to keenly monitor this evolving situation, which not only reflects on Regeneron Pharmaceuticals but also on the integrity of financial practices throughout the healthcare market overall.
Investors are particularly concerned about several undisclosed practices related to the sales of Eylea, a medication developed by Regeneron. According to the lawsuit, it is alleged that the company engaged in arrangements where it paid credit card fees to its distributors. Impressively, these arrangements stipulated that distributors should not impose additional charges on customers who opted to use credit cards for purchasing Eylea. This practice raises concerns about price inflation, as it effectively allowed Regeneron to subsidize costs, offering a deceptive appearance of reduced prices to end consumers.
The lawsuit claims that the company’s exemptions provided a competitive edge in a market sensitive to pricing — especially among retina practices that often prioritize cost efficiency when using credit cards to purchase anti-VEGF medications. By not openly reporting these credit card fee payments as price concessions, the lawsuit suggests that Regeneron artificially inflated its sales figures for Eylea.
This misleading behavior not only skewed Regeneron's perceived profitability but also violated federal regulations by overstating the Average Selling Price (ASP) reported to governmental bodies. Such actions allegedly contravene the False Claims Act, further complicating the company's legal standing.
Now, affected investors are being encouraged to participate before the deadline of March 10, 2025, which marks the conclusion for lead plaintiff applications. To be included in the lawsuit, investors don't need to take proactive measures immediately. They have the option to engage legal counsel of their choosing or remain an absent member of the class action.
For those interested in asserting their rights or seeking further information, Glancy Prongay & Murray LLP has offered resources for contacting their offices. Investors are advised to reach out, ensuring to provide necessary details such as mailing address, phone number, and shares purchased in connection to Regeneron Pharmaceuticals.
In the broader perspective, this unfolding scenario highlights crucial elements of corporate responsibility and investor protection within the healthcare sector. The potential outcomes of this lawsuit could have far-reaching implications, not only for Regeneron but also for the standards of disclosures and ethical practices across the pharmaceutical industry as a whole. Investors remain hopeful that justice and transparency prevail, allowing them to reclaim their financial losses and contribute to a more accountable corporate landscape.
As the case develops, updates will likely continue to emerge, shedding further light on the ongoing struggles between pharmaceutical corporations and their investors. Stakeholders and observers are highly advised to keenly monitor this evolving situation, which not only reflects on Regeneron Pharmaceuticals but also on the integrity of financial practices throughout the healthcare market overall.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.